Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.
Ettinger, DS; Wood, DE; Aisner, DL; Akerley, W; Bauman, J; Chirieac, LR; D'Amico, TA; DeCamp, MM; Dilling, TJ; Dobelbower, M; Doebele, RC; Govindan, R; Gubens, MA; Hennon, M; Horn, L; Komaki, R; Lackner, RP; Lanuti, M; Leal, TA; Leisch, LJ; Lilenbaum, R; Lin, J; Loo, BW; Martins, R; Otterson, GA; Reckamp, K; Riely, GJ; Schild, SE; Shapiro, TA; Stevenson, J; Swanson, SJ; Tauer, K; Yang, SC; Gregory, K; Hughes, M
Volume / Issue
Start / End Page
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)